UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39045 IGM Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 77-0349194 (State or other jurisdiction of incorporation or organization) 325 E. Middlefield Road Mountain View, CA 94043 (Address of principal executive offices) (Zip Code) (I. ...

IGM Biosciences, Inc. (NASDAQ:IGMS) Q4 2020 Earnings Conference Call March 30, 2021 4:30 PM ET Company Participants Fred Schwarzer - President and Chief Executive Officer Misbah Tahir - Chief Financial Officer Bruce Keyt - Chief Scientific Officer Daniel Chen - Chief Medical Officer Conference Call Participants Stephen Willey - Stifel, Nicolaus & Company, Inc. Michael Schmidt - Guggenheim Securities, LLC Brian Abrahams - RBC Capital Markets Asthika Goonewardene - Truist Securities, Inc. Operator Good day, e ...

Table of Contents Index to Financial Statements UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K (Mark One) ☒ ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 | Title of each class | Trading Symbol(s) | Name of each exchange on which registered | | --- | --- | --- | | Common Stock, par value $0.01 per share | IGMS | The Nasdaq Global Select Market | For the fiscal year ended December 31, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 O ...

Pioneering the Development of Engineered IgM Antibodies ASH 2020 Investor Conference Call December 5, 2020 Forward-Looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") with respect to the Company's future financial condition, results of operations, business strategy, expectations, milestones and plans. All statements other tha ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | | | | | | | | November 2020 | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") wi ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39045 IGM Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 77-0349194 (State or other jurisd ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | | | | | | | | September 2020 | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") w ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | | | | | | | | Wedbush PacGrow Healthcare Conference | | | | | | | August 2020 | | | | | | | | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q (Mark One) ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2020 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to Commission File Number: 001-39045 IGM Biosciences, Inc. (Exact Name of Registrant as Specified in its Charter) Delaware 77-0349194 (State or other jurisdictio ...

| --- | --- | --- | --- | --- | --- | |----------------------------------------------------------|-------|-------|-------|-------|-------| | | | | | | | | Pioneering the Development of Engineered IgM Antibodies | | | | | | | May 2020 | | | | | | Forward-looking Statements This presentation contains "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995 that reflect the current views of IGM Biosciences, Inc. (the "Company," "we" or "our") with respect to the C ...